The economic burden of diabetes and the benefits of improved glycemic control: The potential role of a continuous glucose monitoring system

Diabetes Technology and Therapeutics

Volumn 2, Issue SUPPL. 1, 2000, Pages

  Skyler, J S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

BEHAVIOR MODIFICATION; BLOOD GLUCOSE MONITORING; CONFERENCE PAPER; CONTINUOUS GLUCOSE MONITORING SYSTEM; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; HEALTH CARE COST; HOSPITAL COST; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING HOME; PATIENT CARE; PRIORITY JOURNAL; SELF CARE;

EID: 0034493835     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/15209150050214069     Document Type: Conference Paper

References (35)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus
3. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
4. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
6. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes
7. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
8. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men
9. The association of glycemia and cause-specific mortality in a diabetic population
10. Resource utilization and costs of care in the Diabetes Control and Complications Trial
11. Patient-level estimates of the cost of complications in diabetes in a managed care population
12. The progressive cost of complications in type 2 diabetes mellitus
13. Economic consequences of diabetes mellitus in the U.S. in 1997
14. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus
15. The cost to health plans of poor glycemic control
16. The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial
17. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14
18. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analysis in the Cholesterol and Recurrent Events (CARE) Trial
19. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
20. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
21. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
22. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
23. Standards of medical care for patients with diabetes mellitus
24. Frequency of blood glucose monitoring in relation to glycaemic control: Observational study with diabetes database
25. Blood-glucose self-monitoring in insulin treated type 2 diabetes mellitus: A cross-sectional study with an intervention group
26. Multiple daily self-glucose monitoring: Its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections
27. Self-monitoring of blood glucose in type 1 diabetic patients: Comparison with continuous microdialysis measurements of glucose in subcutaneous adipose tissue during ordinary life conditions
28. Validation of home blood glucose meters with respect to clinical and analytical approaches
29. The MiniMed Continuous Glucose Monitoring System (CGMS)
30. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: A pilot study
31. Performance evaluation of the MiniMed® Continuous Glucose Monitoring System during patient home use